MyoKardia Inc logo

MYOK - MyoKardia Inc News Story

$224.91 0.0  0.0%

Last Trade - 16/11/20

Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £n/a
Position in Universe th / 6858

BUZZ-Street View: MyoKardia acquisition brings strategic fit to Bristol Myers Squibb

Tue 6th October, 2020 10:07am
** Drugmaker Bristol Myers Squibb Co  BMY.N  said on Monday
it would buy MyoKardia Inc  MYOK.O  for about $13 bln to bolster
its portfolio of heart disease treatments, ahead of the
potential loss of sales exclusivity of some of its blockbuster
    ** Credit Suisse downgrades MYOK to "neutral" and raises PT
to $225 from $136 and believes MYOK acquisition provides a
strong strategic fit for BMY, bolstering its cardiovascular
    ** Brokerage believes the deal terms reflect substantial
value for MYOK's lead heart drug candidate, Mavacamten, and
other pipeline assets, including genetic dilated cardiomyopathy
drug Danicamtiv 
    ** J.P.Morgan also downgrades MYOK to "neutral" and raises
PT to $225 from $131, says while the acquisition comes at a
premium, Mavacamten represents a potential multi-billion annual
sales opportunity for BMY
    ** Brokerage sees the potential for BMY to expand the
diagnosed patient market over time; says the MYOK deal is
expected to be modestly dilutive to 2021 and accretive beginning
in 2023 for BMY
    ** Cowen and Company says BMY's acquisition of MYOK bolsters
an area of existing strength with promising cardiovascular (CV)
assets, but adds clinical and regulatory risk at a steep price
    ** Morningstar says the $13.1 bln price looks reasonable and
MYOK's Mavacamten will likely help BMY to navigate the heavy
patent losses over the next few years

 (Reporting by Aniruddha Chakrabarty)
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.